← Back to Screener
Cumberland Pharmaceuticals Inc (CPIX)
Price$3.15
Favorite Metrics
Price vs S&P 500 (26W)-15.12%
Price vs S&P 500 (4W)4.64%
Market Capitalization$48.31M
All Metrics
P/CF (Annual)9.79x
Book Value / Share (Quarterly)$1.66
P/TBV (Annual)5.49x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)1.95%
Cash Flow / Share (Quarterly)$0.32
Price vs S&P 500 (YTD)-22.98%
Gross Margin (TTM)85.02%
Net Profit Margin (TTM)-6.37%
EPS (TTM)$-0.19
10-Day Avg Trading Volume0.04M
EPS Excl Extra (TTM)$-0.19
Revenue Growth (5Y)3.53%
EPS (Annual)$-0.19
ROI (Annual)-9.42%
Gross Margin (Annual)85.02%
Net Profit Margin (5Y Avg)-12.47%
Cash / Share (Quarterly)$0.77
Revenue Growth QoQ (YoY)31.08%
ROA (Last FY)-3.69%
Revenue Growth TTM (YoY)17.57%
EBITD / Share (TTM)$0.08
ROE (5Y Avg)-16.90%
Operating Margin (TTM)-6.27%
Cash Flow / Share (Annual)$0.32
P/B Ratio1.94x
P/B Ratio (Quarterly)2.39x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)0.95x
Net Interest Coverage (TTM)-145.11x
ROA (TTM)-4.04%
EV / EBITDA (TTM)33.88x
EPS Incl Extra (Annual)$-0.19
Current Ratio (Annual)1.01x
Quick Ratio (Quarterly)0.77x
3-Month Avg Trading Volume0.17M
52-Week Price Return-28.70%
EV / Free Cash Flow (Annual)8.86x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.73
P/S Ratio (Annual)1.09x
Asset Turnover (Annual)0.58x
52-Week High$6.27
Operating Margin (5Y Avg)-16.47%
EPS Excl Extra (Annual)$-0.19
CapEx CAGR (5Y)-38.72%
Tangible BV CAGR (5Y)-10.50%
26-Week Price Return-6.38%
Quick Ratio (Annual)0.77x
13-Week Price Return-33.81%
Total Debt / Equity (Annual)0.21x
Current Ratio (Quarterly)1.01x
Enterprise Value$42.106
Revenue / Share Growth (5Y)3.95%
Asset Turnover (TTM)0.63x
Book Value / Share Growth (5Y)-11.89%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.30x
Pretax Margin (Annual)-6.31%
Cash / Share (Annual)$0.77
3-Month Return Std Dev74.71%
Gross Margin (5Y Avg)82.24%
Net Income / Employee (TTM)$-0
ROE (Last FY)-11.40%
Net Interest Coverage (Annual)-1.34x
EPS Basic Excl Extra (Annual)$-0.19
P/FCF (TTM)7.24x
Receivables Turnover (TTM)3.11x
EV / Free Cash Flow (TTM)8.86x
Total Debt / Equity (Quarterly)0.21x
EPS Incl Extra (TTM)$-0.19
Receivables Turnover (Annual)3.11x
ROI (TTM)-8.82%
P/S Ratio (TTM)1.09x
Pretax Margin (5Y Avg)-13.61%
Revenue / Share (Annual)$3.00
Tangible BV / Share (Annual)$0.73
Free OCF CAGR (5Y)7.49%
Price vs S&P 500 (52W)-63.79%
Year-to-Date Return-18.84%
5-Day Price Return3.53%
EPS Normalized (Annual)$-0.19
ROA (5Y Avg)-6.02%
Net Profit Margin (Annual)-6.37%
Month-to-Date Return-0.62%
Cash Flow / Share (TTM)$0.12
EBITD / Share (Annual)$0.09
Operating Margin (Annual)-6.27%
LT Debt / Equity (Annual)0.21x
P/CF (TTM)9.79x
ROI (5Y Avg)-11.58%
LT Debt / Equity (Quarterly)0.21x
EPS Basic Excl Extra (TTM)$-0.19
P/TBV (Quarterly)5.49x
P/B Ratio (Annual)2.39x
Inventory Turnover (TTM)1.30x
Pretax Margin (TTM)-6.31%
Book Value / Share (Annual)$1.66
Price vs S&P 500 (13W)-36.68%
Beta-0.28x
P/FCF (Annual)10.17x
Revenue / Share (TTM)$3.06
ROE (TTM)-10.54%
52-Week Low$1.85
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CPIXCumberland Pharmaceuticals Inc | 1.09x | 17.57% | 85.02% | — | $3.15 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Cumberland Pharmaceuticals is a specialty pharmaceutical company that acquires, develops, and commercializes branded prescription drugs targeting hospital acute care, gastroenterology, rheumatology, and oncology. The company generates revenue from its portfolio of FDA-approved brands including Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol, and Vibativ, which it distributes through dedicated US sales divisions and international partner networks.